{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:31:36Z","timestamp":1788489096856,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010763","name":"Zorginstituut Nederland","doi-asserted-by":"publisher","award":["OP1240"],"award-info":[{"award-number":["OP1240"]}],"id":[{"id":"10.13039\/501100010763","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40271-023-00616-z","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T07:25:02Z","timestamp":1676618702000},"page":"255-264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8700-8598","authenticated-orcid":false,"given":"Christine","family":"Bennink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"de Mul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"van der Klift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"Broijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidwine","family":"Tick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"de Jongh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Garvelink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien","family":"Lobbezoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hazelzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"616_CR1","unstructured":"Dinmohamed A. Belangrijke cijfers over hematologische kankersoorten. Utrecht, The Netherlands: 2019:11."},{"issue":"6","key":"616_CR2","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/s2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Beksac M, Pantani L, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7(6):e456\u201368. https:\/\/doi.org\/10.1016\/s2352-3026(20)30099-5.","journal-title":"Lancet Haematol."},{"issue":"6","key":"616_CR3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41408-021-00498-0","volume":"11","author":"S Oliva","year":"2021","unstructured":"Oliva S, Bruinink DHO, Rihova L, et al. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial. Blood Cancer J. 2021;11(6):106. https:\/\/doi.org\/10.1038\/s41408-021-00498-0.","journal-title":"Blood Cancer J"},{"issue":"3","key":"616_CR4","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1080\/10428194.2021.1992763","volume":"63","author":"MR Gaballa","year":"2022","unstructured":"Gaballa MR, Ma J, Tanner MR, et al. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma. 2022;63(3):710\u201321. https:\/\/doi.org\/10.1080\/10428194.2021.1992763.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"616_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","volume":"83","author":"AT Johnsen","year":"2009","unstructured":"Johnsen AT, Tholstrup D, Petersen MA, et al. Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol. 2009;83(2):139\u201348. https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01250.x.","journal-title":"Eur J Haematol"},{"issue":"4","key":"616_CR6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","volume":"89","author":"F Mols","year":"2012","unstructured":"Mols F, Oerlemans s, Vos AH, et al. Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Haematol. 2012;89(4):311\u20139. https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01831.x.","journal-title":"Eur J Haematol"},{"issue":"2","key":"616_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","volume":"22","author":"K Jordan","year":"2014","unstructured":"Jordan K, Proskorovsky I, Lewis P, et al. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer. 2014;22(2):417\u201326. https:\/\/doi.org\/10.1007\/s00520-013-1991-4.","journal-title":"Support Care Cancer"},{"issue":"2","key":"616_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/10428194.2019.1666381","volume":"61","author":"H Ludwig","year":"2020","unstructured":"Ludwig H, P\u00f6nisch W, Knop S, et al. Quality of life in patients with relapsed\/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. Leuk Lymphoma. 2020;61(2):377\u201386. https:\/\/doi.org\/10.1080\/10428194.2019.1666381.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"616_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1177\/1049909116646337","volume":"34","author":"F Kiely","year":"2017","unstructured":"Kiely F, Cran A, Finnerty D, et al. Self-reported quality of life and symptom burden in ambulatory patients with multiple myeloma on disease-modifying treatment. Am J Hosp Palliat Care. 2017;34(7):671\u20136. https:\/\/doi.org\/10.1177\/1049909116646337.","journal-title":"Am J Hosp Palliat Care"},{"issue":"7","key":"616_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000744","volume":"6","author":"MC Bennink","year":"2022","unstructured":"Bennink MC, Stege CAM, Lissenberg-Witte BI, et al. Impact of comorbidities on health-related quality of life in nontransplant eligible patients with newly diagnosed multiple myeloma. Hemasphere. 2022;6(7): e744. https:\/\/doi.org\/10.1097\/hs9.0000000000000744.","journal-title":"Hemasphere."},{"key":"616_CR11","unstructured":"Ministerie van Volksgezondheid Welzijn en Sport. Bestuurlijk akkoord medisch specialistische zorg 2019-2022: Kennis- en exploitatiecentrum Officiele Overheidspublicaties; 2019 [cited 2022]. Available from: https:\/\/open.overheid.nl\/Details\/ronl-28f77d2c-bff3-4907-9bf6-45aa6078309a\/1#panel-gegevens"},{"issue":"3","key":"616_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000366","volume":"4","author":"S Oerlemans","year":"2020","unstructured":"Oerlemans S, Bennink MC, Levin MD, et al. Development of a patient centered outcome set for patients with multiple myeloma to be used in clinical practice. Hemasphere. 2020;4(3): e366. https:\/\/doi.org\/10.1097\/hs9.0000000000000366.","journal-title":"Hemasphere."},{"issue":"3","key":"616_CR13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00277-020-04386-8","volume":"100","author":"HWB Cheng","year":"2021","unstructured":"Cheng HWB, Lam KO. Supportive and palliative care in hemato-oncology: how best to achieve seamless integration and subspecialty development? Ann Hematol. 2021;100(3):601\u20136. https:\/\/doi.org\/10.1007\/s00277-020-04386-8.","journal-title":"Ann Hematol"},{"issue":"6","key":"616_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/bmjqs-2013-002524","volume":"23","author":"MB Boyce","year":"2014","unstructured":"Boyce MB, Browne JP, Greenhalgh J. The experiences of professionals with using information from patient-reported outcome measures to improve the quality of healthcare: a systematic review of qualitative research. BMJ Qual Saf. 2014;23(6):508\u201318. https:\/\/doi.org\/10.1136\/bmjqs-2013-002524.","journal-title":"BMJ Qual Saf"},{"issue":"9","key":"616_CR15","doi-asserted-by":"publisher","first-page":"5253","DOI":"10.1007\/s00520-021-06052-9","volume":"29","author":"C Graupner","year":"2021","unstructured":"Graupner C, Breuking SO, Mul S, et al. Patient-reported outcome measures in oncology: a qualitative study of the healthcare professional\u2019s perspective. Support Care Cancer. 2021;29(9):5253\u201361. https:\/\/doi.org\/10.1007\/s00520-021-06052-9.","journal-title":"Support Care Cancer"},{"issue":"2","key":"616_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/jmrs.421","volume":"68","author":"H Nguyen","year":"2021","unstructured":"Nguyen H, Butow P, Dhillon H, et al. A review of the barriers to using Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs) in routine cancer care. J Med Radiat Sci. 2021;68(2):186\u201395. https:\/\/doi.org\/10.1002\/jmrs.421.","journal-title":"J Med Radiat Sci."},{"issue":"1","key":"616_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s11136-021-02950-x","volume":"31","author":"MM van Muilekom","year":"2022","unstructured":"van Muilekom MM, Teela L, van Oers HA, et al. Patients\u2019 and parents\u2019 perspective on the implementation of patient reported outcome measures in pediatric clinical practice using the KLIK PROM portal. Qual Life Res. 2022;31(1):241\u201354. https:\/\/doi.org\/10.1007\/s11136-021-02950-x.","journal-title":"Qual Life Res"},{"issue":"2","key":"616_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","volume":"11","author":"E Terpos","year":"2021","unstructured":"Terpos E, Mikhael J, Hajek R, et al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021;11(2):40. https:\/\/doi.org\/10.1038\/s41408-021-00432-4.","journal-title":"Blood Cancer J"},{"key":"616_CR19","doi-asserted-by":"crossref","unstructured":"Microsoft. Microsoft Teams, version 1.4.00.22472 ed. https:\/\/www.microsoft.com\/nl-nl\/microsoft-teams\/group-chat-software: Microsoft; 2021.","DOI":"10.1007\/978-1-4842-5875-0_1"},{"issue":"2","key":"616_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"key":"616_CR21","unstructured":"ATLAS.ti Scientific Software Development GmbH. ATLAS.ti 22 Windows. 2022."},{"issue":"1","key":"616_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1634\/theoncologist.2012-0113","volume":"18","author":"A Teitelbaum","year":"2013","unstructured":"Teitelbaum A, BA-Mancini A, Huang H, et al. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist. 2013;18(1):37\u201345. https:\/\/doi.org\/10.1634\/theoncologist.2012-0113.","journal-title":"Oncologist"},{"issue":"2","key":"616_CR23","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1016\/j.clml.2020.09.010","volume":"21","author":"HS Mian","year":"2021","unstructured":"Mian HS, Fiala MA, Wildes TM. Burden of treatment among older adults with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk. 2021;21(2):e152\u20139. https:\/\/doi.org\/10.1016\/j.clml.2020.09.010.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"616_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.007","author":"M Di Maio","year":"2022","unstructured":"Di Maio M, Basch E, Denis F, et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO clinical practice guideline. Ann Oncol. 2022. https:\/\/doi.org\/10.1016\/j.annonc.2022.04.007.","journal-title":"Ann Oncol"},{"issue":"8","key":"616_CR25","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s11136-011-0054-x","volume":"21","author":"CF Snyder","year":"2012","unstructured":"Snyder CF, Aaronson NK, Choucair AK, et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2012;21(8):1305\u201314. https:\/\/doi.org\/10.1007\/s11136-011-0054-x.","journal-title":"Qual Life Res"},{"issue":"3","key":"616_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/0163278717734610","volume":"42","author":"A Conway","year":"2019","unstructured":"Conway A, O\u2019Donnell C, Yates P. The effectiveness of the nurse care coordinator role on patient-reported and health service outcomes: a systematic review. Eval Health Prof. 2019;42(3):263\u201396. https:\/\/doi.org\/10.1177\/0163278717734610.","journal-title":"Eval Health Prof"},{"issue":"34","key":"616_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000012037","volume":"97","author":"X Cheng","year":"2018","unstructured":"Cheng X, Wei S, Zhang H, et al. Nurse-led interventions on quality of life for patients with cancer: a meta-analysis. Medicine (Baltimore). 2018;97(34):e12037. https:\/\/doi.org\/10.1097\/md.0000000000012037.","journal-title":"Medicine (Baltimore)"},{"key":"616_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ctrv.2018.12.007","volume":"73","author":"L Monterosso","year":"2019","unstructured":"Monterosso L, Platt V, Bulsara M, et al. Systematic review and meta-analysis of patient reported outcomes for nurse-led models of survivorship care for adult cancer patients. Cancer Treat Rev. 2019;73:62\u201372. https:\/\/doi.org\/10.1016\/j.ctrv.2018.12.007.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"616_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/bmjqs-2021-013315","volume":"31","author":"J Greenhalgh","year":"2022","unstructured":"Greenhalgh J. Understanding the complexities of collecting and using PRO data in a primary care context. BMJ Qual Saf. 2022;31(3):175\u20138. https:\/\/doi.org\/10.1136\/bmjqs-2021-013315.","journal-title":"BMJ Qual Saf"},{"issue":"11","key":"616_CR30","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1007\/s11136-020-02564-9","volume":"30","author":"AM Stover","year":"2021","unstructured":"Stover AM, Haverman L, van Oers HA, et al. Using an implementation science approach to implement and evaluate patient-reported outcome measures (PROM) initiatives in routine care settings. Qual Life Res. 2021;30(11):3015\u201333. https:\/\/doi.org\/10.1007\/s11136-020-02564-9.","journal-title":"Qual Life Res"},{"issue":"4","key":"616_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1377\/hlthaff.2015.1362","volume":"35","author":"DC Lavallee","year":"2016","unstructured":"Lavallee DC, Chenok KE, Love RM, et al. Incorporating patient-reported outcomes into health care to engage patients and enhance care. Health Aff (Millwood). 2016;35(4):575\u201382. https:\/\/doi.org\/10.1377\/hlthaff.2015.1362.","journal-title":"Health Aff (Millwood)"},{"issue":"8","key":"616_CR32","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1245\/s10434-016-5184-5","volume":"23","author":"OM Fayanju","year":"2016","unstructured":"Fayanju OM, Mayo TL, Spinks TE, et al. Value-based breast cancer care: a multidisciplinary approach for defining patient-centered outcomes. Ann Surg Oncol. 2016;23(8):2385\u201390. https:\/\/doi.org\/10.1245\/s10434-016-5184-5.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"616_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/tbj.12707","volume":"23","author":"SH Javid","year":"2017","unstructured":"Javid SH, Lawrence SO, Lavallee DC. Prioritizing patient-reported outcomes in breast cancer surgery quality improvement. Breast J. 2017;23(2):127\u201337. https:\/\/doi.org\/10.1111\/tbj.12707.","journal-title":"Breast J"},{"issue":"11","key":"616_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.29647","volume":"4","author":"DI Pryor","year":"2021","unstructured":"Pryor DI, Martin JM, Millar JL, et al. Evaluation of hypofractionated radiation therapy use and patient-reported outcomes in men with nonmetastatic prostate cancer in Australia and New Zealand. JAMA Netw Open. 2021;4(11):e2129647. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.29647.","journal-title":"JAMA Netw Open"},{"key":"616_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.oraloncology.2019.09.003","volume":"98","author":"SM Willems","year":"2019","unstructured":"Willems SM, Abeln S, Feenstra KA, et al. The potential use of big data in oncology. Oral Oncol. 2019;98:8\u201312. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.09.003.","journal-title":"Oral Oncol"},{"issue":"6","key":"616_CR36","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.3390\/curroncol29060349","volume":"29","author":"CJG van den Hurk","year":"2022","unstructured":"van den Hurk CJG, Mols F, Eicher M, et al. A narrative review on the collection and use of electronic patient-reported outcomes in cancer survivorship care with emphasis on symptom monitoring. Curr Oncol. 2022;29(6):4370\u201385. https:\/\/doi.org\/10.3390\/curroncol29060349.","journal-title":"Curr Oncol"},{"key":"616_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/shti200172","volume":"270","author":"T Jansen","year":"2020","unstructured":"Jansen T, Geleijnse G, Van Maaren M, et al. Machine learning explainability in breast cancer survival. Stud Health Technol Inform. 2020;270:307\u201311. https:\/\/doi.org\/10.3233\/shti200172.","journal-title":"Stud Health Technol Inform."},{"key":"616_CR38","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3233\/shti220682","volume":"295","author":"D Smits","year":"2022","unstructured":"Smits D, Van Beusekom B, Martin F, et al. An improved infrastructure for privacy-preserving analysis of patient data. Stud Health Technol Inform. 2022;295:144\u20137. https:\/\/doi.org\/10.3233\/shti220682.","journal-title":"Stud Health Technol Inform."},{"issue":"1","key":"616_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4274\/balkanmedj.2017.0966","volume":"35","author":"M Kayaalp","year":"2018","unstructured":"Kayaalp M. Patient privacy in the era of big data. Balkan Med J. 2018;35(1):8\u201317. https:\/\/doi.org\/10.4274\/balkanmedj.2017.0966.","journal-title":"Balkan Med J"},{"issue":"1","key":"616_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41591-018-0272-7","volume":"25","author":"WN Price 2nd","year":"2019","unstructured":"Price WN 2nd, Cohen IG. Privacy in the age of medical big data. Nat Med. 2019;25(1):37\u201343. https:\/\/doi.org\/10.1038\/s41591-018-0272-7.","journal-title":"Nat Med"},{"issue":"12","key":"616_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244546","volume":"15","author":"A Neubert","year":"2020","unstructured":"Neubert A, Brito Fernandes O, Lucevic A, et al. Understanding the use of patient-reported data by health care insurers: a scoping review. PLoS ONE. 2020;15(12):e0244546. https:\/\/doi.org\/10.1371\/journal.pone.0244546.","journal-title":"PLoS ONE"},{"issue":"6","key":"616_CR42","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.37765\/ajmc.2022.89162","volume":"28","author":"J Hanmer","year":"2022","unstructured":"Hanmer J, Cizik AM, Gulek BG, et al. A scoping review of US insurers\u2019 use of patient-reported outcomes. Am J Manag Care. 2022;28(6):e232\u20138. https:\/\/doi.org\/10.37765\/ajmc.2022.89162.","journal-title":"Am J Manag Care"},{"issue":"10","key":"616_CR43","doi-asserted-by":"publisher","first-page":"e1078","DOI":"10.1200\/jop.19.00569","volume":"16","author":"H Theroux","year":"2020","unstructured":"Theroux H, Williams A, Liu M, et al. Multiple myeloma cost of care under the oncology care model: the influence of high-cost therapies. JCO Oncol Pract. 2020;16(10):e1078\u201384. https:\/\/doi.org\/10.1200\/jop.19.00569.","journal-title":"JCO Oncol Pract."},{"key":"616_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jcpo.2017.12.001","volume":"15","author":"N Nixon","year":"2018","unstructured":"Nixon N, Spackman E, Clement F, et al. Cost-effectiveness of symptom monitoring with patient-reported outcomes during routine cancer treatment. J Cancer Policy. 2018;15:32\u20136.","journal-title":"J Cancer Policy"},{"issue":"6","key":"616_CR45","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jtho.2019.02.005","volume":"14","author":"T Lizee","year":"2019","unstructured":"Lizee T, Basch E, Tremoliers P, et al. Cost-effectiveness of web-based patient-reported outcome surveillance in patients with lung cancer. J Thorac Oncol. 2019;14(6):1012\u201320. https:\/\/doi.org\/10.1016\/j.jtho.2019.02.005.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"616_CR46","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1182\/blood.2022016958","volume":"140","author":"HM Blommestein","year":"2022","unstructured":"Blommestein HM, Zweegman S. Cost-effectiveness: maximizing impact by meticulous data. Blood. 2022;140(6):525\u20136. https:\/\/doi.org\/10.1182\/blood.2022016958.","journal-title":"Blood"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-023-00616-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-023-00616-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-023-00616-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T13:31:09Z","timestamp":1682083869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-023-00616-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["616"],"URL":"https:\/\/doi.org\/10.1007\/s40271-023-00616-z","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"assertion":[{"value":"17 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received funding from the National Health Care Institute (Zorginstituut Nederland), OP1240.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PS received research grants from Amgen, Celgene, Janssen and Skyline Dx, honoraria from Amgen, BMS\/Celgene, Janssen, Karyopharm and Seagen, and is the Chairman of the European Myeloma Network and Co-Chairman of HOVON Myeloma Working Group. JH is an independent consultant. AB is on the advisory boards and has received honoraria from Amgen, Janssen, BMS and Sanofi. CB, MM, MK, LT, EJ, MG and DL have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was not required (MEC-2022-0001).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written consent was obtained from all patients, verbal consent was obtained from all other participants prior to the interview.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants provided verbal consent for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and analysed during the current study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"CB, MdM, DL, PS and JH contributed to the conception and design. CB, MvdK, AB, LT, EdJ and MG participated in the data collection. CB, MdM and JH performed the analysis and drafted the first version of the manuscript. All authors critically read, revised and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Written consent was obtained from all patients, verbal consent was obtained from all other participants prior to the\ninterview. All participants provided verbal consent for publication.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}